Table 1. Expression of EMP3, p85, p-Akt, uPA, MMP-9 in relation to patient characteristics and pathological features of hepatocellular carcinoma.

Characteristic	Number of patients (%)		p Value	Number of patients (%)		p Value	Number of patients (%)		p Value	Number of patients (%)		p Value	Number of patients (%)		p Value
	EMP3(-)	EMP3(+)		p85(-)	p85 (+)		p-Akt(-)	p-Akt(+)		uPA(-)	uPA(+)		MMP-9(-)	MMP-9(+)
Total number of patients	35 (47.3)	39 (52.7)		19 (25.7)	55 (74.3)		36 (48.6)	38 (41.4)		18 (24.3)	56 (75.7)		12 (16.2)	62 (83.8)
Age (year)
<50	15 (46.9)	17(53.1)	0.568	9 (28.1)	23(71.9)	0.437	15(46.9)	17(53.1)	0.487	11(34.4)	21(65.6)	0.103	8 (25.0)	24 (75.0)	0.111
≥50	20 (47.6)	22 (52.4)		10 (23.8)	32 (76.2)		21 (50.0)	21 (50.0)		7(16.7)	35 (83.3)		4 (9.5)	38 (90.5)
Gender
Male	35 (48.6)	37(51.4)	0.274	19 (26.4)	53 (73.6)	0.551	34 (47.2)	38 (52.8)	0.233	18 (25)	54 (75)	0.570	12(16.7)	60 (83.3)	0.700
Female	0 (0)	2 (100)		0 (0)	2 (100)		2 (100)	0 (0)		0 (0)	2 (100)		0 (0)	2 (100)
Differentiated
well	5 (83.3)	1 (16.7)	<0.031	3 (50)	3 (50)	<0.018	4 (66.7)	2 (33.3)	<0.037	2 (33.3)	4 (66.7)	<0.034	2 (33.3)	4 (66.7)	<0.009
moderately	18 (56.3)	14 (43.7)		11 (34.4)	21(65.6)		20(62.5)	12 (37.5)		11 (34.4)	21 (65.6)		9 (28.1)	23(71.9)
poorly	12 (33.3)	24 (66.7)		5 (13.9)	31 (86.1)		12 (33.3)	24 (66.7)		4 (11.1)	32 (88.9)		1 (2.8)	35 (97.2)
Tumor stage
I+II	18 (52.9)	16 (47.1)	0.254	4 (11.8)	30 (88.2)	<0.016	13 (38.2)	21 (61.8)	0.078	5 (14.7)	29 (85.3)	0.167	4 (11.8)	30 (88.2)	0.263
III+IV	17 (42.5)	23 (57.5)		15 (37.5)	25 (62.5)		23 (57.5)	27 (42.5)		13 (32.5)	27 (67.5)		8 (20.0)	32 (80.0)